Published in:
Open Access
28-02-2023 | Systemic Therapy | ASO Author Reflections
ASO Author Reflections: Patient-Reported Outcomes of the CAIRO6 Phase II Trial
Authors:
Checca Bakkers, MD, PhD, Koen P. Rovers, MD, PhD, Anouk Rijken, MD, Simon W. Nienhuijs, MD, PhD, Ignace H. J. T. de Hingh, MD, PhD
Published in:
Annals of Surgical Oncology
|
Issue 5/2023
Login to get access
Excerpt
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has been recommended in most (inter)national guidelines for selected patients with colorectal peritoneal metastases (CPM).
1 While the additional benefit of HIPEC after CRS is currently a topic of discussion, there is also no consensus on the role of perioperative systemic therapy in addition to CRS/HIPEC for resectable CPM. As a result, the administration and timing of perioperative systemic therapy in this patient group is heterogenous worldwide, and insight into its efficacy and burden is lacking.
2 In the absence of clinical trials investigating this topic, the CAIRO6 trial was commenced in 2017.
3 This investigator-initiated, parallel-group, open-label, phase II/III, superiority trial randomizes patients with resectable CPM to upfront CRS/HIPEC alone or CRS/HIPEC with perioperative systemic therapy. As part of the phase II trial, patient-reported outcomes (PROs) were compared between both treatment groups to evaluate the burden of perioperative systemic therapy in this setting.
4 …
